Author:
Al-Obaidi Hisham,Granger Amy,Hibbard Thomas,Opesanwo Sefinat
Abstract
It is well established that currently available inhaled drug formulations are associated with extremely low lung deposition. Currently available technologies alleviate this low deposition problem via mixing the drug with inert larger particles, such as lactose monohydrate. Those inert particles are retained in the inhalation device or impacted in the throat and swallowed, allowing the smaller drug particles to continue their journey towards the lungs. While this seems like a practical approach, in some formulations, the ratio between the carrier to drug particles can be as much as 30 to 1. This limitation becomes more critical when treating lung conditions that inherently require large doses of the drug, such as antibiotics and antivirals that treat lung infections and anticancer drugs. The focus of this review article is to review the recent advancements in carrier free technologies that are based on coamorphous solid dispersions and cocrystals that can improve flow properties, and help with delivering larger doses of the drug to the lungs.
Reference193 articles.
1. Diseases of the Respiratory System;Moss;New Complet. Med. Health Encycl.,1997
2. Alveolar epithelial cells type II are major target cells forC. pneumoniaein chronic but not in acute respiratory infection
3. Advancement in pulmonary drug delivery systems for treatment of tuberculosis;Goyal,2017
4. Mycobacterium tuberculosis
Pathogenesis and Molecular Determinants of Virulence
5. Global Impact of Respiratory Disease,2017
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献